Kos Announces Presentation at the Deutsche Bank 2006 Healthcare Conference
25 April 2006 - 7:09PM
Business Wire
Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced that Adrian
Adams, President and Chief Executive Officer, will present at the
Deutsche Bank 2006 Healthcare Conference, which is being held May 2
- May 3, 2006 in Boston, MA. Kos' presentation will take place at
10:30 am ET on Wednesday, May 3, 2006. Interested parties can
access the webcast information by going to the investor relations
section of Kos' website at www.kospharm.com, and referencing
upcoming events. About Kos Kos Pharmaceuticals, Inc. is a fully
integrated specialty pharmaceutical company engaged in developing,
commercializing, manufacturing and marketing proprietary
prescription products for the treatment of chronic diseases with a
particular focus on the cardiovascular, metabolic and respiratory
disease areas. The Company's principal product development strategy
is to reformulate existing pharmaceutical products with large
market potential to improve safety, efficacy, and patient
compliance. Kos' strategy also includes making measured investments
in new chemical entity research through in-house and sponsored
research, scientific in-licensing and general corporate development
activities. The Company currently markets Niaspan(R) and Advicor(R)
for the treatment of cholesterol disorders, Azmacort(R) for the
treatment of asthma, Cardizem(R)LA for the treatment of
hypertension and angina, and Teveten(R) and Teveten(R)HCT for the
treatment of hypertension. Kos has a strong and growing research
and development pipeline including proprietary drug delivery
technologies in solid-dose, inhalation and aerosol metered-dose
device administration to help fuel sustained, organic sales growth
into the future. Certain statements in this press release,
including statements relating to the Company's strong and growing
research and development pipeline and future sales growth are
forward-looking and are subject to risks and uncertainties which
may cause actual results to differ materially from those projected
in a forward-looking statement. These risks and uncertainties
include the Company's ability to successfully develop and
commercialize new products under development, the Company's ability
to enter into new business development and corporate opportunities,
the progress of the company's research and development pipeline,
the protection afforded by the Company's patents, the effect of
conditions in the pharmaceutical industry and the economy in
general, and the Company's ability to maintain compliance with FDA.
A more detailed discussion of risks attendant to the
forward-looking statements included in this press release are set
forth in the "Forward-Looking information: Certain Cautionary
Statements" section of the Company's Annual Report on Form 10-K for
the year ended December 31, 2005, filed with the Securities and
Exchange Commission, and in other reports filed with the SEC.
Kos (NASDAQ:KOSP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Kos (NASDAQ:KOSP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Kos Pharmaceuticals (NASDAQ): 0 Nachrichtenartikel
Weitere Kos Pharmaceuticals, Inc. News-Artikel